Physician profile
Michael A Manbeck
NPI 1649272725
$5,067.25
in general payments reported to CMS, 2019-2025
22 companies · $585 in 2025
The $585 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $348 · 2021: $1,007 · 2022: $867 · 2023: $756 · 2024: $834 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,175.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,871.97 | 2019-2025 | |
| Gilead Sciences, INC. | $442.33 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $376.39 | 2020-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $321.08 | 2019-2022 | |
| Celgene Corporation | $246.02 | 2021-2024 | Zeposia |
| Pfizer INC. | $148.03 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $145.80 | 2021-2022 | |
| Amgen INC. | $138.28 | 2021-2025 | Avsola, Amjevita |
| Janssen Biotech, INC. | $58.52 | 2019-2023 | Stelara |
| Mauna Kea Technologies, INC. | $57.15 | 2020-2024 | |
| Intuitive Surgical, INC. | $39.92 | 2019 | |
| Intercept Pharmaceuticals, INC. | $35.88 | 2020-2021 | |
| Shionogi INC | $34.22 | 2019 | |
| Redhill Biopharma INC. | $24.26 | 2020 | |
| Sirtex Medical INC | $22.61 | 2024 | Sir-Spheres Microspheres |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $19.73 | 2022 | |
| Vivus LLC | $17.85 | 2019 | |
| Boston Scientific Corporation | $16.13 | 2024 | Watchman Flx |
| Organon LLC | $14.25 | 2023 | Renflexis |
| Amag Pharmaceuticals, INC. | $12.73 | 2021 | |
| Allergan, INC. | $12.09 | 2019 | |
| Braintree Laboratories, INC. | $12.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Manbeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.